2,257 material Form 8-K filings that 1,923 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Hallador Energy reported third-quarter 2026 results with total revenue of $130.3 million, down 11% from a year earlier but up 28% from the second quarter. The company posted a net loss of $4.5 million, compared with net income of $23.9 million a year earlier, and total debt rose to $551.9 million after a $600 million construction bridge loan tied to its Turtle Creek gas project, which it targets for a final investment decision before the end of 2026.
Q3 2026 total revenue was $130.3 million, down from $146.6 million in Q3 2025 and up from $101.5 million in Q2 2026.
Net loss was $4.5 million, versus net income of $23.9 million in Q3 2025 and a net loss of $15.2 million in Q2 2026.
Adjusted EBITDA was $17.3 million, compared with $24.9 million in Q3 2025.
Total debt rose to $551.9 million at September 30, 2026, from $45.0 million at June 30, 2026, after a $600 million senior secured construction bridge loan facility.
Douglas Elliman reported third-quarter 2026 net income of $7.4 million, or $0.08 per diluted share, compared with a net loss of $24.7 million a year earlier, while revenue fell to $252.1 million from $262.8 million. Adjusted EBITDA was a $5.3 million loss versus $1.0 million of income, and the company also approved a $10 million share repurchase program, which it says will be funded from cash on hand.
Q3 2026 revenue was $252.1 million vs. $262.8 million in Q3 2025; the company sold its property management business in October 2025.
Q3 operating income was $6.3 million vs. an operating loss of $10.7 million; Adjusted EBITDA was a $5.3 million loss vs. $1.0 million of income.
Nine-month revenue was $749.9 million vs. $787.6 million, and the net loss narrowed to $11.6 million ($0.14 per share) from $53.3 million ($0.63 per share).
The Board approved a $10 million share repurchase program; cash and a Treasury bill totaled about $123 million with no long-term debt as of September 30, 2026.
Rani Therapeutics reported third-quarter 2026 results with contract revenue of $1.7 million, up from none a year earlier, mainly from its Chugai collaboration. Net loss rose to $8.8 million from $7.9 million as research and development and general and administrative expenses increased, and cash, cash equivalents and marketable securities fell to $45.3 million, which the company says will fund operations at least through the end of 2027.
Contract revenue was $1.7 million for the quarter ended September 30, 2026, versus no contract revenue a year earlier.
Net loss attributable to Rani was $7.7 million, compared with $5.4 million in the prior-year quarter; net loss per Class A share was $0.04, versus $0.12.
Cash, cash equivalents and marketable securities were $45.3 million at September 30, 2026, down from $53.4 million at June 30, 2026.
In October 2026 the RaniPill platform was accepted into the FDA's Emerging Technology Program; RT-114 expansion cohort data are expected by the end of 2026.
Bain Capital Specialty Finance (BCSF) reported third-quarter 2026 net investment income of $27.7 million, or $0.43 per share, down from $28.6 million, or $0.44 per share, in the second quarter. Net increase in net assets from operations rose to $0.26 per share from $0.22, while net asset value per share fell to $16.49 from $16.65. The company also declared a fourth-quarter dividend of $0.42 per share and appointed Amrit Kanwal as an independent director, expanding the board to nine members.
Q3 2026 net investment income was $27.7 million, or $0.43 per share, versus $28.6 million, or $0.44 per share, in Q2 2026; total investment income was $59.9 million, versus $62.3 million.
Net increase in net assets from operations was $16.7 million, or $0.26 per share, versus $0.22 per share in Q2 2026; net asset value per share was $16.49 at September 30, 2026, versus $16.65 at June 30, 2026.
Board declared a fourth-quarter 2026 dividend of $0.42 per share, with a record date of December 15, 2026 and payment on or before December 29, 2026.
Amrit Kanwal, 61, was appointed an independent Class III director effective November 4, 2026, and joined the Audit, Nominating and Corporate Governance, and Compensation Committees.
Nine Energy Service reported third quarter 2026 revenue of $142.0 million, essentially unchanged from the second quarter's $141.8 million. Net loss widened to $5.1 million, or $(0.36) per share, from $4.9 million, or $(0.35) per share, and adjusted EBITDA fell to $8.3 million from $8.6 million. For shareholders, the company expects fourth quarter revenue to be flat and profitability to be modestly higher than the third quarter.
Q3 2026 revenue of $142.0 million versus $141.8 million in Q2 2026; cementing revenue rose 11% quarter over quarter.
Net loss of $5.1 million ($0.36 per share) in Q3 2026 versus $4.9 million ($0.35 per share) in Q2 2026.
Adjusted EBITDA of $8.3 million in Q3 2026 versus $8.6 million in Q2 2026.
Management expects Q4 2026 revenue to be flat and profitability to be modestly higher than Q3; total liquidity was $46.0 million at September 30, 2026.
Exodus Movement reported third quarter 2026 revenue of $32.5 million, up 7% from $30.3 million a year earlier, but swung to a net loss of $8.3 million attributable to the company from net income of $17.0 million in the prior-year quarter. General and administrative expenses rose 94% to $28.9 million, and the company said it expects to cut combined annual costs by about $30 million going into 2027 following the Monavate and Baanx acquisitions.
Q3 2026 revenue was $32.5 million, up 7% from $30.3 million in Q3 2025
Net loss attributable to Exodus was $8.3 million, versus net income of $17.0 million a year earlier
Adjusted EBITDA was a loss of $3.9 million, compared with positive $5.9 million in Q3 2025
Exodus is on track to reduce combined annual costs by about $30 million going into 2027
Novanta reported third quarter 2026 results on November 9, 2026. GAAP revenue rose 23% to $305 million, while GAAP net income fell to $2 million from $10.7 million and GAAP diluted EPS fell to $0.05 from $0.30. The company also updated its full-year 2026 outlook, now expecting GAAP revenue of $1,135 million to $1,140 million, and said it closed its largest acquisition in company history, Riverpoint Medical.
Q3 2026 GAAP revenue was $305 million, up 23.1% from $247.8 million; Adjusted EBITDA rose 38.3% to $80.3 million.
GAAP operating income was $13.9 million versus $21.8 million a year earlier, and restructuring, acquisition, and related costs were $23.1 million.
Adjusted diluted EPS was $1.05, up 20.7% from $0.87; operating cash flow was $39.3 million versus $8.5 million.
For full-year 2026, the company now expects GAAP revenue of $1,135 million to $1,140 million and Adjusted EBITDA of $274 million to $277 million.
Bakkt reported third-quarter 2026 revenue of $149.2 million, down 62.9% from $402.2 million a year earlier, mainly due to lower crypto trading volume and the loss of clients. The company posted net income of $14.3 million, or $0.31 per diluted share, versus a net loss of $14.9 million in Q3 2025, and the filing notes the result includes a $26.8 million non-cash gain on the Transchem warrants. It reiterated a full-year 2026 Total Transacting Volume target of approximately $3 billion and set a first-half 2027 target of approximately $6 billion.
Q3 2026 total revenue was $149.2 million versus $402.2 million in Q3 2025; net income attributable to Bakkt was $14.3 million, or $0.31 per diluted share
Adjusted EBITDA loss narrowed to $11.8 million from $14.8 million in Q3 2025 on a consistent basis
TTV was $147.9 million for Q3 2026; the company reiterated its approximately $3 billion full-year 2026 target and set an approximately $6 billion first-half 2027 target
Cash, cash equivalents and restricted cash were $37.3 million as of September 30, 2026, versus $50.7 million as of June 30, 2026
Ranger Energy Services reported third quarter 2026 revenue of $162.8 million, up from $128.9 million a year earlier but down from $176.5 million in the second quarter, with net income of $2.5 million or $0.10 per diluted share. The company also declared a quarterly dividend of $0.06 per share, payable December 4, 2026, which signals continued cash returns to shareholders.
Q3 2026 revenue was $162.8 million, versus $176.5 million in Q2 2026 and $128.9 million in Q3 2025
Net income was $2.5 million, or $0.10 per diluted share, versus $0.29 per diluted share in Q2 2026 and $0.05 in Q3 2025
Adjusted EBITDA was $20.1 million, down from $28.6 million in Q2 2026 but up from $16.8 million in Q3 2025
Quarterly dividend of $0.06 per share payable December 4, 2026, to holders of record on November 20, 2026
Perspective Therapeutics reported a third-quarter 2026 net loss of $32.4 million, or $0.27 per share, up from $26.0 million, or $0.35 per share, a year earlier, as research and development spending rose. Cash, cash equivalents and short-term investments were about $202 million at September 30, 2026, which the company says should fund planned clinical milestones and operations into 2028.
Q3 2026 net loss was $32.4 million ($0.27 per share), versus $26.0 million ($0.35 per share) in Q3 2025; weighted average shares rose to 120.7 million from 74.3 million.
Research and development expenses were $26.1 million, up from $20.3 million; general and administrative expenses were $8.3 million, up from $7.7 million.
Cash, cash equivalents and short-term investments were about $202 million at September 30, 2026, versus about $145 million at December 31, 2025.
On October 2026, the FDA granted Fast Track Designation to PSV359 for FAP-positive solitary fibrous tumors.
JBS N.V. reported third-quarter 2026 results on November 9, 2026. Net sales rose 1% from a year earlier to $22.7 billion, but IFRS adjusted EBITDA fell 36% to $1,181 million and earnings per share fell to $0.15 from $0.52. Net leverage rose to 3.54x from 2.39x, which shows weaker profit and higher debt relative to earnings.
Net sales of $22.7 billion, up 1% from $22.6 billion in 3Q25
IFRS adjusted EBITDA of $1,181 million, down 36%; adjusted EPS of $0.16 vs. $0.54
Free cash flow was negative $167 million in 3Q26 vs. positive $383.5 million in 3Q25
Revolving credit facility raised to $4.2 billion from $3.5 billion; total liquidity of $8.2 billion
Viant Technology reported third-quarter 2026 revenue of $110.4 million, up 29% year-over-year, and adjusted EBITDA of $19.8 million, up 24%. GAAP net income attributable to Viant fell to $67 thousand, or $0.00 per share, from $996 thousand, or $0.06 per share, a year earlier. The board also raised the share repurchase authorization by $50 million to $150 million total, with $70.8 million remaining.
Q3 2026 revenue was $110.4 million, up 29% from $85.6 million; GAAP net income attributable to Viant was $67 thousand, down 93%
Non-GAAP adjusted EBITDA was $19.8 million, up 24%; non-GAAP diluted EPS was $0.13 versus $0.12
Q4 2026 guidance: revenue of $130.5 million to $133.5 million and adjusted EBITDA of $31.0 million to $32.0 million
Repurchase authorization increased by $50 million to $150 million, effective November 9, 2026, with $70.8 million remaining
Green Dot reported third-quarter 2026 results, with GAAP total operating revenues up 21% year over year and a narrower net loss. Adjusted EBITDA rose 9%, but non-GAAP diluted EPS fell 17%. The company will not hold an earnings call or give 2026 guidance because of its pending sale to Smith Ventures and CommerceOne, which is expected to close by the first quarter of 2027.
Third-quarter GAAP total operating revenues were $601.1 million, up 21% from $494.8 million a year earlier.
GAAP net loss was $7.4 million, or $0.13 per diluted share, compared with a net loss of $30.8 million, or $0.56 per share, in the prior-year quarter.
Adjusted EBITDA was $25.8 million, up 9%, while non-GAAP diluted EPS was $0.05 compared with $0.06 a year earlier.
No 2026 financial guidance or earnings call, due to the proposed transactions; the 2026 Annual Meeting is set for December 21, 2026.
Office Properties Income Trust reported results for the quarter ended September 30, 2026, with a net loss of $45.8 million, or $2.09 per share, and normalized FFO of $20.5 million, or $0.93 per share. Rental income rose to $114.2 million from $109.1 million a year earlier, and the company sold 13 properties in the quarter and issued $425 million of new senior secured notes.
Rental income was $114.2 million for the quarter, up from $109.1 million in the same quarter of 2025.
Net loss was $45.8 million, or $2.09 per share, and normalized FFO was $20.5 million, or $0.93 per share.
Same property cash basis NOI was $51.5 million, a 14.8% increase year over year.
Issued $425 million of 8.75% senior secured notes due 2031 and repaid a $325 million revolving credit facility and a $100 million term loan due January 2027.
Gladstone Investment Corporation reported net investment income of $4.8 million, or $0.12 per share, for the quarter ended September 30, 2026, down from $15.9 million, or $0.40 per share, in the prior quarter. Total investment income fell 14.8% to $24.2 million, while the net increase in net assets from operations rose to $17.1 million, helped by net unrealized appreciation, and net asset value per share rose to $16.43 from $16.24.
Net investment income was $4.8 million, or $0.12 per share, versus $15.9 million, or $0.40 per share, in the June 30, 2026 quarter.
Total investment income was $24.2 million, down from $28.4 million, mainly due to a $5.6 million decrease in success fee income.
Net increase in net assets from operations was $17.1 million, or $0.43 per share, compared with a decrease of $11.9 million, or $0.30 per share, in the prior quarter.
The quarterly distribution was $0.24 per share, unchanged from the prior quarter, and Walter H. Wilkinson Jr. resigned from the board on October 22, 2026.
Rackspace Technology reported third-quarter 2026 revenue of $609 million, down 9.3% from a year earlier, with Public Cloud revenue down 17.2% and Private Cloud revenue up 4.2%. The net loss narrowed to $54 million, or $0.21 per share, from $67 million, or $0.28 per share, a year earlier. The company raised its full-year 2026 revenue outlook by $35 million at the midpoint and kept its non-GAAP operating profit and Adjusted EBITDA outlook unchanged.
Q3 2026 revenue was $609 million, down 9.3% from $671 million in Q3 2025; Public Cloud fell 17.2% to $349 million and Private Cloud rose 4.2% to $260 million.
Net loss narrowed to $54 million ($0.21 per share) from $67 million ($0.28 per share); non-GAAP operating profit rose 12% to $36 million.
Full-year 2026 total revenue outlook is $2.51 billion to $2.56 billion, raised by $35 million at the midpoint; the profit outlook was maintained.
As of September 30, 2026, cash and cash equivalents were $108 million and total liquidity was $170 million; Q3 capital expenditures were $104 million.
U.S. Physical Therapy furnished a transcript of its November 5, 2026 third-quarter earnings call, in which it reported revenue up 13% to $223 million and adjusted earnings per share of $0.80, up $0.14 from a year earlier. It reaffirmed full-year EBITDA guidance of $102 million to $106 million, but reported a GAAP loss per share of $1.04 versus earnings of $0.48 a year earlier, which the company attributed to changes in the value of partner ownership stakes in subsidiaries.
Q3 2026 total revenue was $223 million, up 13%; comparable revenue rose 7%.
Q3 2026 EBITDA was $28 million, up $4 million; adjusted EPS was $0.80, up $0.14.
GAAP net income attributable to shareholders was $11 million, versus $13 million a year earlier, and GAAP loss per share was $1.04.
Full-year 2026 EBITDA guidance of $102 million to $106 million was reaffirmed; credit facility borrowings were $247 million versus $162 million at year-end 2025.
Occidental reported third-quarter 2026 net income attributable to common stockholders of $1.6 billion, or $1.61 per diluted share, and adjusted income of $2.0 billion, or $1.91 per share. Both measures fell from the second quarter, with the decline mainly reflecting lower realized crude prices, a sharp drop in midstream and marketing income, and derivatives losses. The company reduced principal debt by $1.8 billion to $10.0 billion, and production of 1,427 Mboed exceeded the midpoint of guidance.
Reported EPS $1.61 versus $2.75 in Q2 2026; adjusted EPS $1.91 versus $2.40 in Q2 2026
Pre-tax income from oil and gas $2.6 billion versus $2.8 billion in Q2; midstream and marketing pre-tax income $55 million versus $1.3 billion in Q2
Operating cash flow of $4.1 billion and free cash flow before working capital of $2.8 billion, with capital expenditures of $1.3 billion
Principal debt reduced to $10.0 billion after retiring $10.4 billion of debt since the start of 2026
Casella Waste Systems reported third-quarter 2026 revenue of $559.2 million, up 15.2%, and adjusted EBITDA of $133.5 million, up 11.4%. GAAP results moved the other way: the company posted a net loss of $7.0 million, compared with net income of $10.0 million a year earlier, after a $13.6 million landfill development impairment charge. The company raised its 2026 revenue guidance, narrowed its adjusted EBITDA guidance, and now expects a full-year net loss instead of net income.
Q3 revenue was $559.2 million, up $73.9 million, or 15.2%, from the same period in 2025; adjusted EBITDA was $133.5 million, up 11.4%.
Q3 net loss was $(7.0) million, or $(0.11) per diluted share, versus net income of $10.0 million, or $0.16 per share, in Q3 2025; the period included a $13.6 million landfill development impairment charge.
2026 guidance: revenue raised to $2.100 billion to $2.110 billion; adjusted EBITDA narrowed to $475 million to $481 million; net loss guidance of $(10) million to $(4) million replaces prior net income guidance of $0 million to $6 million.
H&R Block reported fiscal 2027 first-quarter revenue of $224.3 million, up 10.2% from the prior year, but its net loss from continuing operations widened to $188.1 million and its loss per share rose to $1.53. The company reaffirmed its full-year fiscal 2027 outlook and declared a quarterly dividend of $0.46 per share, which matters to shareholders because revenue growth is offset by a larger loss, while guidance was held unchanged.
Total revenue was $224.3 million, up $20.8 million, or 10.2%, from the prior year period.
Net loss from continuing operations was $188.1 million, up 13.8%; loss per share from continuing operations was $1.53, up 21.4%.
Adjusted loss per share was $1.40, compared with $1.20 a year earlier; the company cited a higher net loss and fewer shares outstanding after buybacks.
The company repurchased 2.2 million shares for $100.3 million in the quarter and declared a $0.46 dividend payable January 6, 2027.
Hims & Hers reported third-quarter 2026 revenue of $890.4 million, up 49% from a year earlier, and subscribers rose 13% to 2,788 thousand. The company swung to a net loss of $33.0 million from net income of $15.8 million a year earlier, and it reduced its full-year 2026 Adjusted EBITDA guidance to $257 million to $277 million while narrowing revenue guidance to $3.13 billion to $3.15 billion. Shareholders face higher reported losses and a lower profit outlook even as sales grew.
Q3 2026 revenue was $890.4 million, up 49% from $599.0 million, with gross margin falling to 57% from 74%.
Net loss was $33.0 million versus net income of $15.8 million in Q3 2025; Adjusted EBITDA rose to $82.4 million from $78.4 million.
Full-year 2026 Adjusted EBITDA guidance was reduced to $257 million to $277 million; full-year revenue guidance was tightened to $3.13 billion to $3.15 billion.
Q3 free cash flow was $26.0 million, down from $79.4 million a year earlier.
Take-Two Interactive reported fiscal second-quarter 2027 results for the period ended September 30, 2026. Net Bookings fell 18% and GAAP net revenue declined, but the GAAP net loss narrowed from a year earlier, and the company reiterated its fiscal 2027 Net Bookings outlook of $8.0 to $8.2 billion.
Net Bookings of $1.60 billion, down 18% from $1.96 billion a year earlier
GAAP net revenue of $1.50 billion versus $1.77 billion; GAAP net loss of $54.0 million, or $0.29 per share, versus $133.9 million, or $0.73 per share
Grand Theft Auto VI release date listed as November 19, 2026
AAON reported third-quarter 2026 net sales of $707.4 million, up 84.1%, and diluted EPS of $0.83, up 124.3%, and raised its full-year 2026 sales growth outlook to 72%-75% from 55%-60%. The company also said it is restating its first- and second-quarter 2026 financial statements over calculation errors and has identified a material weakness in internal controls, which shareholders should weigh alongside the stronger results.
Q3 2026 net sales rose 84.1% to $707.4 million; operating income rose 129.3% to $100.0 million.
Q3 gross margin was 26.7%, down from 27.8% a year earlier but up 60 basis points from the second quarter.
Restatement: Q1 2026 net income is $36.5 million, down $3.4 million; six-month net income is $103.6 million, up $7.1 million.
The material weakness will be reported in the Q3 2026 Form 10-Q; Forms 10-Q/A for Q1 and Q2 were filed with this 8-K.
Rocket Lab reported third-quarter 2026 results on November 9, 2026, with revenue of $268 million, up from $155 million a year earlier. The net loss widened to $79.7 million, or $0.12 per share, compared with $18.3 million, or $0.03 per share, in the third quarter of 2025. The company guided fourth-quarter 2026 revenue to $270 million to $290 million, so shareholders get a higher revenue base but a larger loss to weigh against it.
Q3 2026 revenue was $267.8 million, up 73% from $155.1 million in Q3 2025 and $34 million above Q2 2026.
GAAP operating loss was $79.2 million; net loss was $79.7 million, or $0.12 per share, versus $0.03 per share a year earlier.
Backlog grew to approximately $3.6 billion, up 52% from the end of Q2 2026.
Fourth-quarter 2026 guidance: revenue of $270 million to $290 million and GAAP gross margin of 34% to 36%.
Sharplink reported third-quarter 2026 results with total revenue up 24% year over year to $13.5 million and net income of $751.4 million, or $3.45 per diluted share, versus $104.3 million, or $0.62, a year earlier. The quarterly profit was driven mainly by $676.7 million of unrealized gains on crypto assets, while the nine-month period still showed a net loss of $328.4 million after $268.8 million of crypto asset impairments, so the results depend heavily on ETH market prices.
Q3 2026 total revenue was $13.5 million, up from $10.8 million; staking revenue rose 27% to $13.1 million.
Q3 net income was $751.4 million ($3.45 diluted EPS), including $676.7 million unrealized and $75.2 million realized gains on crypto assets.
Nine-month 2026 net loss was $328.4 million, or $1.55 per share, including $268.8 million in impairments of crypto assets at cost.
Crypto assets at fair value were $1.6 billion at September 30, 2026; ETH holdings were 892,708 as of that date and 895,117 as of November 2, 2026.
MARA Holdings reported results for the quarter ended September 30, 2026. Revenue fell 35% to $164.2 million from $252.4 million a year earlier, while net income rose to $632.1 million, or $1.28 per diluted share, mainly because of an $885.3 million gain on digital assets. After quarter-end, the board authorized a share repurchase program of up to $500.0 million, which gives shareholders a new capital return option.
Revenue was $164.2 million, down from $252.4 million in Q3 2025; the company cited a 37% decline in the average price of bitcoin mined.
Net income was $632.1 million, or $1.28 per diluted share, compared with $123.1 million, or $0.27 per diluted share, in Q3 2025. The result includes an $885.3 million gain related to the fair value of digital assets.
After quarter-end, the board authorized a share repurchase program of up to $500.0 million of common stock.
After quarter-end, the company repaid $750.0 million of bitcoin-collateralized term loans and reported $1.4 billion of total debt reduction year to date.
Skydance Corporation reported third-quarter 2026 results for Paramount Skydance, which excludes Warner Bros. Discovery because that acquisition closed on October 6, 2026. Revenue rose 5% to $7.0 billion and net earnings were $73 million, but adjusted EBITDA was flat year over year at $1.0 billion, and the company now expects a Q4 Studios profit impact of up to $200 million from weaker Warner Bros. film results. Gross debt was $87 billion following the acquisition, which shareholders should weigh against the company's stated goal of reducing net leverage to 3.0x by the end of 2029.
Q3 total revenue was $7.0 billion, up 5% year over year; net earnings were $73 million, diluted EPS $0.06, and adjusted EBITDA $1.0 billion at a 14.2% margin.
Operating income was $368 million, including $187 million of restructuring and transaction-related costs.
Studios Q4 profit impact of up to $200 million versus prior expectations, due to underperformance of the Warner Bros. film slate; Paramount Skydance standalone remains on track for the high end of its $3.9 billion 2026 profitability outlook
Warner Bros. Discovery acquisition completed October 6, 2026, funded with $47 billion of new equity and $57 billion of new secured debt.
AMC Global Media reported third-quarter 2026 revenue of $566.1 million, up 0.8% from a year earlier, but swung to a GAAP diluted loss of $1.13 per share from earnings of $1.38. The results include an $85 million charge for a legal settlement and $81.3 million in impairment and other charges, while adjusted EPS rose to $0.44 from $0.18.
Net revenues were $566.1 million, up 0.8% from $561.7 million; nine-month revenues fell 3.6% to $1.66 billion.
Operating loss was $41.6 million, compared with operating income of $55.5 million a year earlier; diluted EPS was $(1.13) versus $1.38.
An $85 million charge was recorded for the settlement of a breach of contract suit; total settlement consideration is $120 million, with $35 million due by January 31, 2027.
Adjusted operating income was $70.4 million, down 25.4% from $94.4 million, and free cash flow was $(52.4) million.
HighPeak Energy reported a third-quarter 2026 net loss of $55.7 million, wider than the $18.3 million loss a year earlier, while revenue rose to $256.8 million from $208.7 million. The company raised its 2026 production range and increased its capital expenditure range to $310 million to $320 million, and it said a pending refinancing would replace its $1.2 billion term loan. The filing notes the refinancing may not be completed on the contemplated terms or at all.
Q3 2026 net loss of $55.7 million, or $(0.44) per diluted share, vs. a net loss of $18.3 million, or $(0.15), in Q3 2025; loss on derivative instruments of $107.5 million
Adjusted net income of $38.5 million, or $0.32 per diluted share; EBITDAX of $163.8 million; free cash flow of $22.4 million
2026 outlook: production raised to 44,500 to 45,500 Boe/d; lease operating expenses lowered to $8.00 to $8.25 per Boe; total capital expenditures raised to $310 million to $320 million
Pending refinancing: $450 million preferred equity investment and $800 million credit facility, with the $1.2 billion term loan to be paid off; closing expected later in November 2026
Oxbridge Re Holdings reported results for the quarter and nine months ended September 30, 2026. The third-quarter net loss widened because net premiums earned fell, while the nine-month net loss narrowed because no underwriting losses were recorded in 2026, compared with a loss-heavy 2025 period. The company also said AI GridWorks, launched in August 2026, is evaluating sites and power for data center projects.
Q3 2026 net loss was $421,000 ($0.05 per share), up from $187,000 ($0.02 per share) a year earlier, as net premiums earned fell to $86,000 from $555,000.
Nine-month net loss narrowed to $223,000 ($0.03 per share) from $2.19 million ($0.30 per share), with no underwriting losses recorded in 2026.
Cash and restricted cash rose to $19.57 million at September 30, 2026, from $6.98 million at December 31, 2025.
SurancePlus completed five tokenized reinsurance offerings for 2026–2027 with approximately $7.1 million in aggregate gross offering proceeds.
Public Policy Holding Company reported third-quarter 2026 revenue of $55.2 million, up 13.2%, and GAAP net income of $0.2 million, compared with a $7.4 million loss a year earlier. The GAAP result was supported by a $9.8 million non-cash bargain purchase gain on acquisitions, while adjusted EPS, fully diluted, fell to $0.33 from $0.36 on a higher share count. The company reaffirmed its full-year 2026 guidance.
Q3 2026 revenue of $55.2 million, up 13.2%; organic revenue growth of 5.1%
GAAP net income of $0.2 million vs. a net loss of $7.4 million in Q3 2025, including a $9.8 million bargain purchase gain
Adjusted EPS, fully diluted, of $0.33 vs. $0.36 in Q3 2025; nine-month revenue of $157.5 million, up 15.2%
Full-year 2026 guidance reaffirmed: revenue of $213 million to $216 million and Adjusted EBITDA of $48.5 million to $50.5 million
Amaero reported third quarter 2026 revenue of $4.1 million, up 35% year-over-year, and guided to fourth quarter revenue of $4.5 million to $5.0 million. The net loss attributable to stockholders widened to $9.1 million, or $0.38 per share, from $4.1 million, or $0.20 per share, a year earlier, and the company posted a $4.4 million gross loss after a titanium production pause and sieving system optimization. For shareholders, revenue growth is offset by a larger loss, and the company says it expects revenue growth to drive operating leverage and gross margin improvement.
Q3 2026 revenue of $4.1 million, up 35% from $3.1 million; nine-month revenue of $11.5 million, up 170%
Net loss of $9.1 million, or $0.38 per share, versus $4.1 million, or $0.20 per share, in Q3 2025; gross loss of $4.4 million
Q4 2026 revenue guidance of $4.5 million to $5.0 million; full year 2026 revenue guidance of $16.0 million to $16.5 million
IPO completed October 16, 2026 with net proceeds of $17.0 million; cash and cash equivalents were $19.3 million as of October 31, 2026
Xenon reported third-quarter 2026 results with no revenue in either period, a net loss of $110.4 million versus $90.9 million a year earlier, and higher research and development and general and administrative spending. Loss per share narrowed to $1.11 from $1.15, and the company said its cash funds operations into 2029. Shareholders should note that the X-NOVA2 depression study readout is now expected in December 2026 and that enrollment of new patients in the depression and bipolar Phase 3 studies was paused in September.
Net loss was $110.4 million for Q3 2026 versus $90.9 million for Q3 2025; loss per share was $1.11 versus $1.15.
No revenue was recorded in Q3 2026 or Q3 2025. Research and development expenses rose to $95.6 million from $77.1 million.
Cash, cash equivalents and marketable securities were $1,153.5 million at September 30, 2026, compared with $586.0 million at December 31, 2025.
The azetukalner New Drug Application for focal seizures was submitted to the FDA in September 2026; X-NOVA2 topline data are now expected in December 2026.
Cincinnati Financial posted investor presentation slides on November 9, 2026 for use from November 10, 2026. The slides show third-quarter 2026 EPS of $2.96 versus $7.11 in 3Q25, while non-GAAP operating income was $443 million compared with $449 million, and the combined ratio rose to 90.9%. The company said its year-to-date value creation ratio of 5.8% was below its 10% to 13% long-term target.
3Q26 EPS of $2.96 per share versus $7.11 per share in 3Q25
Non-GAAP operating income of $443 million versus $449 million in 3Q25
Combined ratio of 90.9%, 2.7 percentage points higher than 3Q25, including 7.0 points from higher catastrophe losses
YTD 9-30-26 value creation ratio of 5.8%, below the 10% to 13% target; P&C net written premiums grew 4%
Somnigroup released an updated investor presentation on November 9, 2026, alongside its third-quarter 2026 results. Third-quarter net sales rose 10.8% to $2,351 million, and adjusted EPS rose to $1.04 from $0.95, but GAAP net income fell 7.8% to $164 million and GAAP EPS fell to $0.74 from $0.83. The company's 2026 outlook calls for adjusted EPS of $2.90 at the midpoint and sales of approximately $8.65 billion.
Q3 2026 net sales were $2,351 million, up from $2,123 million in Q3 2025
Q3 2026 GAAP EPS was $0.74, down from $0.83; adjusted EPS was $1.04, up from $0.95
Q3 2026 adjusted EBITDA was $448 million, up from $419 million
2026 outlook: adjusted EPS of $2.90 at the midpoint and sales of approximately $8.65 billion
Fervo Energy reported third-quarter 2026 results, with net income of $11.7 million driven largely by a $29.9 million tax benefit and an $11.8 million non-cash swap gain, while operating loss widened to $43.7 million from $13.7 million a year earlier. The company lowered its expected second-half 2026 capital spending to $700 million to $750 million from $850 million to $900 million, and said Cape Google 400 commercial operation dates are unchanged, which matters for shareholders weighing construction costs and timing.
Q3 2026 net income of $11.7 million, versus a net loss of $15.8 million in Q3 2025; the release cites $15.4 million of interest income and two non-recurring items
Q3 2026 operating loss of $43.7 million; general and administrative expense rose to $39.4 million from $27.4 million in Q2 2026
Second-half 2026 capital expenditure outlook cut to $700 million to $750 million from $850 million to $900 million, with no change to expected commercial operation dates
Signed a 15-year take-or-pay power purchase agreement with Google for 396 megawatts, with first power expected mid-2028
Safe Harbor reported third-quarter 2026 revenue of $1.95 million, up 6.5%, while swinging to a net loss of approximately $979,000 from net income a year earlier that included a $3.34 million debt extinguishment gain. The company also disclosed a nonbinding term sheet with Opifex Media Inc. under which Opifex security holders would own about 85% of the combined company, and the company's common share count rose sharply after Series B conversions, which shareholders should weigh against these results.
Q3 2026 revenue was $1.95 million, up from $1.83 million; net loss was approximately $979,000, or $0.95 per share, versus net income of approximately $180,000 in Q3 2025.
Nonbinding term sheet with Opifex Media Inc. signed October 23, 2026; Opifex holders would own approximately 85% of the combined company's fully diluted shares, with the Safe Harbor share adjustable from 12.5% to 17.5%.
Series B conversion price reset to $0.1210 on October 22, 2026; common shares outstanding rose from 1,028,702 on September 30 to 132,248,520 on November 6, 2026.
Nasdaq granted an additional period through April 19, 2027 to regain compliance with the $1 minimum bid price; cash was $4.4 million at September 30, 2026, and the filing includes a going concern disclosure.
OPAL Fuels reported third quarter 2026 revenue of $79.5 million, down 5% from a year earlier, while Adjusted EBITDA rose 32% to $26.7 million and net income was $1.7 million versus a $1.9 million loss. The company now expects 2026 RNG production to be modestly below its guidance range and expects full-year Adjusted EBITDA at the lower end of its guidance range, which it maintained, so shareholders face weaker production expectations even as profit measures improved.
Q3 2026 revenue was $79.5 million, down 5% from $83.4 million in Q3 2025; nine-month revenue was $236.3 million, down 5%.
Q3 2026 Adjusted EBITDA was $26.7 million, up from $20.2 million; net income was $1.7 million versus a $1.9 million loss; basic and diluted EPS was $(0.03), unchanged year over year.
Company now expects 2026 RNG production to be modestly below its guidance range; 2026 Adjusted EBITDA guidance was maintained, with results expected at the lower end of the range.
Three new RNG projects with about 2.0 million MMBtu of annual design capacity are expected to begin commercial operations over 2027.
Quanterix reported third-quarter 2026 revenue of $35.0 million, up 6.3% from the second quarter but down from $40.2 million a year earlier, and a net loss of $21.6 million, compared with $33.5 million a year earlier. The company narrowed its 2026 total revenue outlook to $142-146 million, which gives shareholders a clearer range for the full year.
Q3 2026 revenue of $35.0 million, compared with $40.2 million in Q3 2025 and up 6.3% from Q2 2026.
Net loss of $21.6 million, or $0.46 per share, compared with a net loss of $33.5 million, or $0.73 per share, a year earlier.
2026 total revenue outlook narrowed to $142-146 million; adjusted gross margin expectation of 48-50% unchanged; year-end cash expected at about $70 million with no debt.
Cash, cash equivalents, marketable securities and restricted cash totaled $80.7 million at September 30, 2026.
Uniti Group reported third quarter 2026 revenue of $848.1 million, up from $722.6 million a year earlier, but posted a net loss of $244.5 million, compared with net income of $1,608.9 million in the prior-year quarter that included a $1,685.4 million gain on settlement of preexisting relationships. Adjusted EBITDA was $289.3 million, down from $327.8 million, and the company raised its full-year 2026 revenue outlook to $3.665 billion to $3.695 billion while projecting a net loss of $590 million to $620 million.
Third quarter revenue of $848.1 million, up from $722.6 million in the same quarter of 2025
Net loss of $244.5 million, versus net income of $1,608.9 million in the prior-year quarter, which included a $1,685.4 million settlement gain
Adjusted EBITDA of $289.3 million, down from $327.8 million a year earlier
2026 outlook: revenue of $3.665 billion to $3.695 billion, net loss of $590 million to $620 million, and Adjusted EBITDA of $1.46 billion to $1.49 billion
Turning Point Brands reported third-quarter 2026 results, with net sales up 27.0% to $151.1 million, driven by growth in its Modern Oral products. Net income attributable to the company fell 81.4% to $3.9 million, and diluted EPS was $0.19 versus $1.13 a year earlier, as sales and marketing spending increased. The company reaffirmed its full-year 2026 guidance, which it had last updated on September 21, 2026.
Net sales rose 27.0% to $151.1 million; Modern Oral net sales rose 102.9% to $74.4 million.
Net income attributable to Turning Point Brands fell 81.4% to $3.9 million; diluted EPS was $0.19 versus $1.13.
Adjusted EBITDA fell 41.3% to $18.4 million, including increased sales and marketing investments.
Full-year 2026 guidance reaffirmed: Modern Oral net sales of $260-$270 million and Adjusted EBITDA of $70-$80 million.
WhiteHorse Finance reported third quarter 2026 results for the period ended September 30, 2026, with net investment income of $4.4 million, or $0.207 per share, down from $4.7 million in the prior quarter. Net asset value per share rose to $11.82 from $11.77, and the board declared a $0.25 per share distribution payable January 6, 2027, while the adviser agreed to lower its incentive fee rate to 17.50%.
Net investment income was $4,439 thousand, or $0.207 per share, down 5.2% from $4,681 thousand in Q2 2026; core net investment income rose 2.7% to $4,806 thousand, or $0.224 per share
Net asset value per share increased to $11.82 from $11.77; net realized losses were $3,631 thousand
Quarterly distribution of $0.25 per share payable January 6, 2027 to holders of record as of December 21, 2026; a special distribution of $0.17 per share is payable December 10, 2026
Adviser voluntarily reduced the incentive fee rate from 20.00% to 17.50% for the quarter ending December 31, 2026
CECO Environmental reported third-quarter 2026 revenue of $404.4 million, up 105% from a year earlier, following its June 1, 2026 acquisition of Thermon. The company swung to a GAAP net loss of $2.0 million, though non-GAAP net income rose to $34.3 million. It raised its full-year 2026 orders and free cash flow conversion outlook, kept its revenue and Adjusted EBITDA outlook unchanged, and introduced a 2027 outlook.
Q3 2026 revenue was $404.4 million, up 105%; GAAP net loss was $2.0 million versus net income of $1.5 million a year earlier.
Non-GAAP diluted EPS was $0.60 versus $0.26; Adjusted EBITDA was $70.1 million, up 202%.
2026 orders outlook raised to exceed $2.5 billion from at least $2.0 billion; free cash flow conversion raised to about 100% of Adjusted EBITDA from at least 55%.
2026 revenue ($1.300 billion to $1.375 billion) and Adjusted EBITDA ($200 million to $225 million) outlooks were maintained; 2027 revenue outlook is $2.1 billion to $2.3 billion.
RadNet reported third-quarter 2026 revenue of $638.3 million, up 22.1%, and Adjusted EBITDA of $105.0 million, up 23.8%, both described as records. GAAP net income attributable to common stockholders fell to $4.2 million, or $0.05 per diluted share, from $5.4 million, or $0.07, a year earlier. The company raised its 2026 Imaging Center guidance for revenue, Adjusted EBITDA and free cash flow, and raised Digital Health Adjusted EBITDA guidance.
Q3 2026 revenue was $638.3 million, up from $522.9 million; Adjusted EBITDA was $105.0 million, up from $84.9 million.
GAAP net income attributable to RadNet common stockholders was $4.2 million ($0.05 per diluted share) versus $5.4 million ($0.07) in Q3 2025; adjusted diluted EPS was $0.30 versus $0.24.
Imaging Center guidance raised to $2,385-$2,435 million revenue, $350-$363 million Adjusted EBITDA and $120-$130 million free cash flow.
Digital Health Adjusted EBITDA fell 11.8% to $3.0 million in Q3; cash was $750.6 million at September 30, 2026, and the pending ONRAD acquisition was referenced.
ImmunityBio reported third-quarter 2026 net product revenue of $48.7 million, up 53% from a year earlier, and nine-month net product revenue of $143.6 million, up 92%. Net loss attributable to common stockholders rose to $184.6 million for the quarter from $67.3 million, mainly due to non-cash fair value changes in a related-party convertible note, warrant and derivative liabilities after a higher common stock price, along with higher interest expense and operating costs.
Q3 2026 net product revenue was $48.7 million, up 53% year-over-year; nine-month net product revenue was $143.6 million, up 92%.
Q3 2026 net loss attributable to common stockholders was $184.6 million, versus $67.3 million in Q3 2025; basic loss per share was $0.17 versus $0.07.
Nine-month net loss attributable to common stockholders was $1.0 billion, versus $289.5 million a year earlier.
Cash, cash equivalents and marketable securities totaled $334.3 million as of September 30, 2026.
Tonix Pharmaceuticals reported third-quarter 2026 net product revenue of $17.2 million, up from $3.3 million a year earlier, with TONMYA contributing $15.0 million. The net loss available to common stockholders widened to $53.3 million from $32.0 million, as research and development and selling, general and administrative expenses rose sharply. The company said its cash resources will meet its requirements into the early third quarter of 2027, a timeline shareholders will weigh against the larger losses.
Net product revenue was $17.2 million versus $3.3 million a year earlier; TONMYA net revenue was $15.0 million, up 37% from the second quarter.
Net loss available to common stockholders was $53.3 million, or $2.89 per share, compared with $32.0 million, or $3.59 per share, a year earlier.
R&D expenses were $25.8 million and SG&A expenses were $45.6 million, compared with $9.3 million and $25.7 million a year earlier.
Cash and cash equivalents were about $163 million as of September 30, 2026; the company expects them to fund operations into the early third quarter of 2027.
Roivant reported results for the quarter ended September 30, 2026, its first quarter with sales of LISRAYA (brepocitinib), which launched in August 2026. Revenue rose to $35.1 million from $1.6 million a year earlier, but the net loss attributable to Roivant widened to $191.6 million, or $0.27 per share, from $113.5 million, or $0.17, partly due to $95.9 million of distributions tied to Moderna settlement proceeds.
LISRAYA generated net product revenue of $31.0 million in its first 5 weeks of launch following FDA approval in August 2026.
Net loss attributable to Roivant was $191.6 million, or $0.27 per share, versus $113.5 million, or $0.17 per share, a year earlier.
Net loss included $95.9 million of distributions on Genevant equity awards tied to Moderna settlement proceeds.
Cash, cash equivalents and marketable securities were $4.2 billion as of September 30, 2026.
Powerfleet reported fiscal second-quarter 2027 revenue of $115.7 million, up 4% year over year, but its net loss attributable to common stockholders widened to $6.9 million from $4.3 million. The company said it has agreed in principle to a device financing facility with Rand Merchant Bank, subject to definitive documentation, and affirmed its fiscal 2027 revenue and adjusted EBITDA guidance.
Revenue rose to $115.7 million from $111.7 million, while gross margin fell to 53% from 56%.
Profit from operations was $1.4 million, compared with $4.2 million a year earlier, per the statement of operations.
Agreed in principle to a device financing facility with Rand Merchant Bank; terms remain subject to definitive documentation.
Fiscal 2027 guidance affirmed: revenue of $468 million to $473 million and adjusted EBITDA of $111 million to $114 million.
Superior Group reported third quarter 2026 net sales of $146.0 million, up 5% from $138.5 million a year earlier, but net income fell to $2.6 million, or $0.17 per diluted share, from $2.7 million, or $0.18. The company narrowed its full-year 2026 net sales and adjusted EPS forecasts by raising the low end of each range, which signals somewhat firmer expectations for shareholders.
Q3 2026 net sales of $146.0 million, up 5% from $138.5 million in Q3 2025
Net income of $2.6 million, or $0.17 per diluted share, versus $0.18 a year earlier
Adjusted EBITDA of $6.7 million, down from $7.5 million; CEO cited incremental charges tied to the Healthcare Apparel strategic shift
2026 net sales outlook narrowed to $578.0 million to $585.0 million; adjusted EPS outlook narrowed to $0.60 to $0.66
Hain Celestial reported fiscal first quarter 2027 results for the quarter ended September 30, 2026, with net sales down 29% to $260 million and a net loss of $11 million, narrowed from $21 million a year earlier. The company said final regulatory approvals were received in early November 2026 for the sale of its International business to AURELIUS, but a condition requiring a credit agreement amendment by October 12, 2026 was not satisfied, and discussions on a path forward continue.
Net sales were $260 million, down 29% year over year; organic net sales fell 7%.
Net loss was $11 million, or $0.12 per diluted share, versus $21 million, or $0.23, a year earlier; adjusted EBITDA was $18 million versus $20 million.
Final required regulatory approvals for the International sale to AURELIUS were received in early November 2026.
The credit agreement amendment condition due October 12, 2026 was not satisfied; total debt was $586 million at quarter end.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.